AliFSSchneiderEWArepalliS, et alCoring of intravitreal medication vial stoppers: a report from the Research and Safety in Therapeutics Committee of the American Society of Retina Specialists. J Vitreoretin Dis. 2025;9(5):546-549.
2.
Al-khersanHBusquetsMGhorayebG, et alSupply chain volatility of repackaged intravitreal bevacizumab: a survey of the American Society of Retina Specialists. J Vitreoretin Dis. 2025;9(5):550-554.
3.
LeungEHGrewalDSGerbiE, et alCost-effectiveness of treatments for diabetic macular edema: simulated bevacizumab-first step therapy versus real-world practice. J Vitreoretin Dis. 2025;9(5):555-565.
4.
AmmarMJLeeJJCaiL, et alSurgical outcomes of primary noncomplex rhegmatogenous retinal detachment in 20- to 45-year-old young adults. J Vitreoretin Dis. 2025;9(5):566-574.
5.
BitraJSureshkumarHEatharaAVAlahmadiRHeifermanMJ.Risk factors for recurrent vitreous hemorrhage after 25-gauge pars plana vitrectomy in patients with proliferative diabetic retinopathy. J Vitreoretin Dis. 2025;9(5):575-583.
6.
MontazeriFEmami-NaeiniP.Temporal trends and regional variations in retinal detachment repair procedures in the United States from 2013 to 2021. J Vitreoretin Dis. 2025;9(5):584-591.
7.
RushRBRushSW.Chronic diabetic tractional retinal detachment and poor visual acuity: should we be performing surgery on these patients?J Vitreoretin Dis. 2025;9(5):592-598.
8.
LiuJWirostkoWAhmadB.Incidence of and risk factors for silicone oil–associated cystoid macular edema after pars plana vitrectomy. J Vitreoretin Dis. 2025;9(5):599-606.
9.
EtonEAPanWWBesirliCGZacksDNWubbenTJ.Incidence and impact of outer retinal folds after pars plana vitrectomy for primary rhegmatogenous retinal detachment repair. J Vitreoretin Dis. 2025;9(5):607-613.
10.
Al-AssilTVogtDWolfA, et alAutologous retinal transplant in refractory macular holes. J Vitreoretin Dis. 2025;9(5):614-621.
11.
De ClerckIVan CalsterJStalmansP. Clinical performance of novel single-use lenses in vitreoretinal surgery. J Vitreoretin Dis. 2025;9(5):622-627.
12.
MansourAMLimaLHParodiMBCasellaAMBCherfanDGArevaloJF.Outcomes of and surgical technique for treatment with high-dose aflibercept. J Vitreoretin Dis. 2025;9(5):628-631.
13.
OkawaKMaruyama-InoueMChinJYInoueTYanagiYKadonosonoK.One-year outcomes of intravitreal faricimab injection in treatment-naïve patients with neovascular age-related macular degeneration. J Vitreoretin Dis. 2025;9(5):632-638.
14.
KhaohoenAChantarasornY.Clinical features and optical coherence tomography angiography in neovascular age-related macular degeneration and pachychoroid neovasculopathy. J Vitreoretin Dis. 2025;9(5):639-650.
15.
DhootDSShahCPSilvaFQ, et alImpact of central subfield thickness fluctuations on visual outcomes in neovascular age-related macular degeneration in the VIEW trials. J Vitreoretin Dis. 2025;9(5):651-658.
16.
HoyekSPatelNAParikhAAYaghyAMukaiSBaumalCR.Comparison of adult and pediatric eyes with coats disease using multimodal imaging. J Vitreoretin Dis. 2025;9(5):659-666.
17.
ScripsemaNKAl-KhaledTSongA, et alThe influence of ultra-widefield fluorescein angiography on the diagnosis and management of diabetic retinopathy. J Vitreoretin Dis. 2025;9(5):667-677.
18.
SverdlichenkoITayebSNarmandakhAMargolinETsangDSYanP.Radiation retinopathy after whole-brain radiotherapy in a patient with pineal gland tumor. J Vitreoretin Dis. 2025;9(5):678-686.
19.
DhillonNMacLeodS.Intraocular inflammation following intravitreal faricimab: insights from five bilateral cases. J Vitreoretin Dis. 2025;9(5):687-691.
20.
ShenCLiuDChenC, et alClinical and optical coherence tomography characteristics of severe intraretinal silicone oil migration. J Vitreoretin Dis. 2025;9(5):692-698.
21.
PappasCPWaldieAMShahPR.From vitreous to ventricles: serial imaging of intracranial silicone oil migration. J Vitreoretin Dis. 2025;9(5):699-702.
22.
WolekMPaulSSeralyMMehraASobolW.En face optical coherence tomography and optical coherence tomography angiography for the diagnosis and monitoring of syphilitic posterior placoid chorioretinopathy. J Vitreoretin Dis. 2025;9(5):703-708.
23.
AllanKCKindyAEYuanA.Occam versus hickam: irreversible vision loss from paclitaxel-induced cystoid macular edema. J Vitreoretin Dis. 2025;9(5):709-711.
24.
LinT-HLinHYChuangY-HTsengP-C.Faricimab as treatment for sarcoid uveitis with refractory cystoid macular edema. J Vitreoretin Dis. 2025;9(5):712-716.
25.
ShethNDe AlbaMChallaNMassengillMTMielerWF.Diagnosis of secondary vitreoretinal lymphoma with neurosurgical stereotactic biopsy: a multimodal diagnostic and imaging approach. J Vitreoretin Dis. 2025;9(5):717-721.
26.
AlenaziMMuraMAlakeelyAGAl-QahtaniFS.Human amniotic membrane patch for optic disc pit maculopathy remains integrated at 2 years. J Vitreoretin Dis. 2025;9(5):722-726.
27.
GaoMALiuTRandhawaS.A novel case of optic disc edema associated with VEXAS syndrome. J Vitreoretin Dis. 2025;9(5): 727-730.
